Secukinumab是一种完全人源化的IgG1单克隆抗体,可以选择性地中和促炎性细胞因子白细胞介素17A(IL-17A),而IL-17和IL-23/T17轴在银屑病的发病机制中具有核心作用,因此,IL-17是银屑病治疗中的一个关键靶标。II期临床和III期临床试验研究表明secukinumab作为皮下注射的IL-17抑制剂,在中度至重度斑块型银屑病和银屑病关节炎(PsA)治疗中具有明显的优势,且安全性及耐受性良好。美国FDA于2015年1月已批准其作为治疗成人中度至重度斑块型银屑病的新药申请,是治疗该类疾病的第一个靶向IL-17的上市药物,预计到2020年其销售额将突破10亿美元。

IL-23 and its downstream TH17 cytokines are likely pathogenic in human psoriatic skin, because mRNA for IL-17A, IL-17F, and IL-22 accumulates in cutaneous lesions. Therefore, IL-17 may be a therapeutic target in T cell-driven inflammatory disorders. Novartis is developing secukinumab, a fully human anti-IL-17A monoclonal antibody, for the potential treatment of several indications. Data from several phase II and phase III clinical trials were reported that targeted inhibition of the proinflammatory cytokine IL-17A with secukinumab through sc injection is a valid therapeutic approach and useful in the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis (PsA) with good safety and tolerability. It has been approved by the FDA on January 2015 as the first IL-17 blocking agent for the treatment of moderate-to-severe plaque psoriasis in adult patients. The market is projected to reach about US$1.0 billion in 2020.

天津市应用基础与前沿技术研究计划重点项目(14JCZDJC33500)